




Searching News Database: CTCL
HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
HSMN NewsFeed - 9 May 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 18 Jun 2008
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
HSMN NewsFeed - 8 Aug 2007
BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs
BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 26 Jul 2007
BioCryst Announces Realignment and Strengthening of the Company's Executive Management Team
BioCryst Announces Realignment and Strengthening of the Company's Executive Management Team
HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
HSMN NewsFeed - 1 Feb 2006
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
Additional items found! 11

Members Archive contains
11 additional stories matching:
CTCL
(Password required)
CTCL
(Password required)